Evidence map›Paper›PMID 41009338›Full record

ReviewInternational journal of molecular sciences2025

Distinction Between Proliferative Lupus Nephritis and Membranous Lupus Nephritis Based on Inflammation, NETosis, and Glomerular Exostosin.

Yukihiro Wada, Hiroyuki Okawa, Tetsuya Abe, Kazuhiro Takeuchi, Mariko Kamata, Emiko Takeuchi, Tadahiro Suenaga, Masayuki Iyoda, Yasuo Takeuchi

Abstract readReview
In one paragraph

Review in International journal of molecular sciences, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Article
  2. Review
  3. Not So Benign: Revisiting Pure Membranous Lupus Nephritis.Journal of personalized medicine · 2025
    Review
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Yukihiro WadaDepartment of Nephrology, Kitasato University School of Medicine, Sagamihara 252-0374, Kanagawa, Japan.ORCID 0000-0001-5996-8735
Hiroyuki OkawaDepartment of Nephrology, Kitasato University School of Medicine, Sagamihara 252-0374, Kanagawa, Japan.
Tetsuya AbeDepartment of Nephrology, Kitasato University School of Medicine, Sagamihara 252-0374, Kanagawa, Japan.ORCID 0000-0002-0300-2293
Kazuhiro TakeuchiDepartment of Nephrology, Kitasato University School of Medicine, Sagamihara 252-0374, Kanagawa, Japan.ORCID 0000-0002-3702-3578
Mariko KamataDepartment of Pharmacology, Kitasato University School of Medicine, Sagamihara 252-0374, Kanagawa, Japan.
Emiko TakeuchiDepartment of Immunology, Kitasato University School of Medicine, Sagamihara 252-0374, Kanagawa, Japan.
Tadahiro SuenagaDepartment of Immunology, Kitasato University School of Medicine, Sagamihara 252-0374, Kanagawa, Japan.ORCID 0009-0006-6802-4844
Masayuki IyodaDepartment of Microbiology and Immunology, Showa Medical University School of Medicine, Tokyo 142-8555, Japan.
Yasuo TakeuchiDepartment of Nephrology, Kitasato University School of Medicine, Sagamihara 252-0374, Kanagawa, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Lupus nephritis (LN) is a serious complication of systemic lupus erythematosus that is associated with long-term morbidity and mortality. Pathomorphological findings of LN are broadly divided into proliferative lupus nephritis (PLN) and membranous lupus nephritis (MLN). PLN is characterized by diffuse global or segmental proliferative glomerulonephritis with significant infiltration of inflammatory cells. Type 1 T-helper (Th1) cells, which predominate under inflammatory conditions, and NETosis, as the process of forming neutrophil extracellular traps (NETs), are key factors in the development of PLN. Meanwhile, MLN is characterized by diffuse membranous nephropathy (MN) with global granular subepithelial immune deposits. MLN patients usually experience massive proteinuria, and occasionally show an unfavorable renal prognosis despite aggressive treatment, similar to PLN patients. Intriguingly, in some instances, MLN patients do not show the general immunoserological characteristics of SLE, such as low serum complement and elevated anti-DNA antibody titers. Several reports have indicated an association between Th2 cell dominance and the development of MLN. Moreover, exostosin 1 (EXT1) and exostosin 2 (EXT2) on the glomerular basement membrane have recently been discovered as novel putative antigens for secondary MN, and have been shown to be up-regulated in patients with MLN. To date, many studies have focused on the dissimilarities between PLN and MLN. However, the reason for two polar morphological forms existing within the same disease is not completely clear. The present review addresses published observations on this topic in addition to providing our assertion regarding characteristic NETosis and glomerular EXT1/EXT2 expressions between PLN and MLN.

Indexed as

Extracellular TrapsGlomerulonephritis, MembranousInflammationLupus NephritisN-AcetylglucosaminyltransferasesAnimalsExostosin 1Exostosin 2HumansKidney GlomerulusExostosin 1Exostosin 2N-AcetylglucosaminyltransferasesEXT1/EXT2membranous lupus nephritisNETosisproliferative lupus nephritis

Identifiers

PMID41009338
PMCPMC12470024

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.